Tales from the Chemo Front Benaron's daughter, Molly, was a great source of comfort to her during chemo A DOCTOR BECOMES A PATIENT By Lisa Benaron, MD In 2002 I was a 42-year-old physician and mother of a five-year-old daughter when I found a lump in my breast that...
Bristol-Myers Squibb Continues Strong Financial Performance Led by Double-Digit Global Sales Growth - Bristol-Myers Squibb Company (NYSE:BMY) today reported very strong sales and earnings growth for the second quarter 2008 and announced additional plans to proactively manage costs.'We are making measurable strides against the strategy...
Bristol-Myers Squibb Continues Strong Financial Performance Led by Double-Digit Global Sales Growth Bristol-Myers Squibb Company (NYSE:BMY) today reported very strong sales and earnings growth for the second quarter 2008 and announced additional plans to proactively manage costs.'We are making measurable strides against the strategy we...
Biocon & Abraxis Bioscience Launch Abraxane in India for treatment of Breast Cancer Biocon Ltd, India's pioneering biotechnology Company, and Abraxis BioScience, Inc, a fully integrated biotechonology Company, today announced the launch of ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin...
Biocon, Abraxis launch Abraxane in India to treat breast cancer Indias biotech major Biocon and Abraxis Bioscience, a fully integrated biotechnology company from the US, have launched Abraxane (paclitaxel protein-bound particles for injectable suspension) in India for the treatment of breast cancer after...
::: Biocon and Abraxis BioScience Launch ABRAXANE in India for Treatment of Breast Cancer BANGALORE, India, & LOS ANGELES--(BUSINESS WIRE)--Biocon Limited, India's pioneering biotechnology company, and Abraxis BioScience, Inc.(NASDAQ:ABII), a fully integrated biotechnology company, today announced the launch of ABRAXANE ...
Biocon and Abraxis BioScience Launch ABRAXANE in India for Treatment of Breast Cancer - Biocon Limited, India's pioneering biotechnology company, and Abraxis BioScience, Inc.(NASDAQ:ABII), a fully integrated biotechnology company, today announced the launch of ABRAXANE(R) (paclitaxel protein-bound particles for injectable...
Biocon and Abraxis BioScience Launch ABRAXANE in India for Treatment of Breast Cancer BANGALORE, India, & LOS ANGELES--(BUSINESS WIRE)--Biocon Limited, India's pioneering biotechnology company, and Abraxis BioScience, Inc.(NASDAQ:ABII - News), a fully integrated biotechnology company, today announced the launch of...
Biocon and Abraxis BioScience Launch ABRAXANE in India for Treatment of Breast Cancer BANGALORE, India, & LOS ANGELES--(BUSINESS WIRE)--Biocon Limited, India's pioneering biotechnology company, and Abraxis BioScience, Inc.(NASDAQ:ABII - News), a fully integrated biotechnology company, today announced the launch of...
Biocon and Abraxis BioScience Launch ABRAXANE in India for Treatment of Breast Cancer Biocon Limited, India's pioneering biotechnology company, and Abraxis BioScience, Inc.(ABII), a fully integrated biotechnology company, today announced the launch of ABRAXANE (paclitaxel protein-bound particles for injectable suspension) ...
Biocon and Abraxis Bioscience Launch Abraxane in India for Treatment of Breast Cancer Source : Biocon Limited (Business Wire India) Biocon Limited, India's pioneering biotechnology company, and Abraxis BioScience, Inc.(NASDAQ:ABII), a fully integrated biotechnology company, today announced the launch of ABRAXANE ...
Biocon and Abraxis BioScience Launch ABRAXANE in India for Treatment of Breast Cancer BANGALORE, India, & LOS ANGELES--(BUSINESS WIRE)--Biocon Limited, India's pioneering biotechnology company, and Abraxis BioScience, Inc.(NASDAQ:ABII), a fully integrated biotechnology company, today announced the launch of ABRAXANE ...
Biocon and Abraxis BioScience Launch ABRAXANE in India for Treatment of Breast Cancer BANGALORE, India, & LOS ANGELES--(BUSINESS WIRE)--Biocon Limited, India's pioneering biotechnology company, and Abraxis BioScience, Inc.(NASDAQ: ABII), a fully integrated biotechnology company, today announced the launch of ABRAXANE ...
Biocon and Abraxis BioScience Launch Abraxane in India for Treatment of Breast Cancer - Biocon Limited, India's pioneering biotechnology company, and Abraxis BioScience, Inc.(NASDAQ:ABII), a fully integrated biotechnology company, today announced the launch of ABRAXANE(R) (paclitaxel protein-bound particles for injectable...
Biocon and Abraxis BioScience Launch ABRAXANE in India for Treatment of Breast Cancer , 7:00 AM EST News source: Business Wire Biocon Limited, India's pioneering biotechnology company, and Abraxis BioScience, Inc.(NASDAQ:ABII), a fully integrated biotechnology company, today announced the launch of ABRAXANE(R) (paclitaxel...
Biocon and Abraxis BioScience Launch ABRAXANE in India for Treatment of Breast Cancer Biocon Limited, India's pioneering biotechnology company, and Abraxis BioScience, Inc.(NASDAQ:ABII), a fully integrated biotechnology company, today announced the launch of ABRAXANE(R) (paclitaxel protein-bound particles for injectable...
Biocon to market new breast cancer drug in India Biotechnology major Biocon Ltd will market Abraxane drug of the US-based Abraxis BioScience in India for treating breast cancer, a top company official said here Friday.To be priced at about $400 (Rs.17,200) per 100mg vial in India, the...
Biocon and Abraxis launch breast cancer drug in India Biocon and Abraxis BioScience have launched Abraxane in India for the treatment of breast cancer after failure of combination therapy for metastatic disease or relapse within six months of adjuvant chemotherapy.Abraxane is now available in...
Biocon and Abraxis Launch Breast Cancer Drug in India Biocon and Abraxis BioScience have launched Abraxane in India for the treatment of breast cancer after failure of combination therapy for metastatic disease or relapse within six months of adjuvant chemotherapy.Abraxane is now available...
Biocon and Abraxis launch breast cancer drug in India Abraxane is now available in India as a single-use 100mg vial (as a lyophilized powder, to be reconstituted for intravenous administration).In October 2007, Abraxane was approved by the Drug Controller General of India.
The approval was...
Cancer medicine shortage KUWAIT: Following complaints over a shortage of Taxol, a cancer treatment medicine, at the Hussein Makki Health Center, the Ministry of Health (MoH) is importing 120 ampoules to help remedy the situation.The Center's manager, Adel...
SFDA approved breast cancer drug Abraxane Paclit Abraxis BioScience, Inc., has received approval from the China State Food and Drug Administration to market Abraxane Paclitaxel for injection (Albumin Bound) for the treatment of breast cancer after failure of standard chemotherapy for...
Biocon & Abraxis to introduce breast cancer drug Abraxane in India Biocon Limited and Abraxis BioScience Inc will soon launch the breast cancer drug Abraxane in India.Abraxane (paclitaxel protein-bound particles for injectable suspension is an albumin-bound) is indicated for the treatment of breast...
Abraxis gets Chinese nod for breast cancer drug Abraxane Paclitaxel for injection Abraxis BioScience, Inc., a fully integrated biotechnology company, has received approval from the China State Food and Drug Administration to market Abraxane Paclitaxel for injection (Albumin Bound) for the treatment of breast cancer after...
Abraxis BioScience Announces Approval to Market ABRAXANE for Metastatic Breast Cancer in China Approval of ABRAXANE Based on Pivotal Phase III Randomized Trials in the U.S.and ChinaCompany Developing Infrastructure and Alliances in Asia-Pacific RegionLOS ANGELES--(HSMN NewsFeed)--Abraxis BioScience, Inc.
(NASDAQ:ABII ), a fully...
